005 study

GOTHENBURG, Sweden, May 8, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL), today announced positive results from an open-label extension Phase 1/2a study, ISO-CC-005, of arfolitixorin as part of the first-line treatment regimen in patients with metastatic colorectal cancer (mCRC). Preliminary response assessment data from 19 patients treated for 8-32 weeks showed a best overall response rate (ORR) in 58% of patients (11/19). These patients were treated with the selected dose regimen of 120 mg/m2 arfolitixorin and 5-fluorouracil (5-FU) with either irinotecan or oxaliplatin (ARFIRI/ARFOX) (ref. 1). Best ORR is defined as a greater than 30 % reduction in tumor size from baseline.